Eli Lilly and Company
I · Analyse IA
En bref
Eli Lilly discovers, develops, manufactures, and sells prescription medicines globally. Their product portfolio spans diabetes drugs (Humalog, Mounjaro, Trulicity), obesity treatments (Zepbound), cancer therapies (Verzenio, Jaypirca), immunology drugs (Taltz, Olumiant), and Alzheimer's treatments (Kisubla). The company operates manufacturing facilities and research labs, and recently began licensing its AI drug discovery platform (TuneLab) to other biotech firms [Yahoo Finance].
Eli Lilly is a major pharmaceutical company with a $910,8 billion market cap [Yahoo Finance], known for developing drugs for diabetes, obesity, cancer, and immunology. The company is riding a massive wave of growth driven by its obesity and diabetes medications Mounjaro and Zepbound, which now generate roughly $13 billion combined per quarter [GuruFocus]. Recent positive clinical trial data and a $4,50 billion manufacturing expansion [Yahoo Finance] signal the company's commitment to this lucrative market, though this concentration creates significant execution risk.
Eli Lilly is in exceptional financial health, posting explosive growth and strong profitability metrics [Yahoo Finance].
Score Sentinellis
8,9/10
En bonne santé financière
Capitalisation boursière
$910,8B
Chiffre d'affaires (12 mois)
$65,2B
Explications
Comment nous lisons ces chiffres
Guides en langage clair · sans compte
ROIC vs WACC Explained: How to Tell If a Company Actually Creates Value
What ROIC and WACC are, how to compute both, and why the spread between them is the single most important number in fundamental investing.
LirePiotroski F-Score Explained: A 9-Point Financial Health Check (with a Live Apple Example)
What the Piotroski F-Score is, how to calculate all 9 criteria, and how to read the result. Plain English, with a real Apple walkthrough.
LireAltman Z-Score Explained: Predicting Bankruptcy in 5 Minutes (with Real Examples)
What the Altman Z-Score is, the exact formula, how to read the result, and which version to use for manufacturers vs tech vs private companies.
LireII · Actualités récentes
Ce qui a fait bouger le cours
6 articles · classés par pertinence
- Macro2026-05-20
Eli Lilly Expands TuneLab Access As AI Partnerships Shape R&D Outlook
Simply Wall St
- Macro2026-05-20
Engage Bio Acquired by Lilly to Accelerate Development of Non-Viral Genetic Medicines
Yahoo Finance
- Macro2026-05-20
Collaborative Drug Discovery Partners with Lilly TuneLab to Make Lilly AI/ML Models Available in CDD Vault
Yahoo Finance
- Macro2026-05-20
Bristol Myers to deploy Anthropic's Claude AI model to speed up drug discovery
Yahoo Finance
- Macro2026-05-18
Supreme Court Ruling Puts Eli Lilly Medicaid Risks And Dividend In Focus
Simply Wall St
- Macro2026-05-19
If You Hold This Healthcare ETF, You’re Losing Big
Yahoo Finance
Premium · gratuit avec tout compte
Extreme revenue concentration: Mounjaro and Zepbound now account for the majority of quarterly revenue at roughly $13 billion combined, meaning any manufacturing issues, safety concerns, or demand slowdown would directly threaten overall financial performance [GuruFocus]
Risques
5
Opportunités
5
Signaux d'alerte
3
Direction
10
12 autres constats dans le rapport complet — gratuit avec tout compte.
Débloquer l'analyse complète de Eli Lilly and Company
Créez un compte gratuit pour accéder au rapport complet généré par IA, avec les sources citées dans le texte.
- 5 risques, 5 opportunités et 3 signaux d'alerte — chacun avec sa source
- Plus de 100 indicateurs financiers avec graphiques et comparaisons
- Résumés d'actualités complets avec liens vers les sources
- Équipe dirigeante et rémunération
III · Entreprises similaires
À lire également
Même secteur · Santé — ou santé financière comparable
L'ajouter à votre liste ?